CAMP4 to Participate in Upcoming Investor Conferences
CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotechnology company focused on regRNA-targeting antisense oligonucleotide therapies, has announced its participation in three major upcoming investor conferences.
The company's President & CEO, Josh Mandel-Brehm, will present at:
- Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Virtual corporate presentation on February 12, 2025, at 10:00 a.m. EST
- Leerink Partners Global Healthcare Conference - Fireside chat in Miami, Florida on March 10, 2025, at 4:20 p.m. EST
- Barclays 27th Annual Global Healthcare Conference - One-on-one meetings in Miami, Florida on March 11-12, 2025
The presentations will be webcast live on CAMP4's investor relations website, with replays available for 30 days after the events.
CAMP4 Therapeutics (Nasdaq: CAMP), una compagnia biotecnologica in fase clinica focalizzata sulle terapie a base di oligonucleotidi antisenso mirati al regRNA, ha annunciato la sua partecipazione a tre importanti conferenze per investitori in arrivo.
Il Presidente e CEO dell'azienda, Josh Mandel-Brehm, presenterà:
- Il 35° Annual Healthcare Life Sciences Conference di Oppenheimer - Presentazione aziendale virtuale il 12 febbraio 2025, alle 10:00 EST
- Conferenza globale sulla salute di Leerink Partners - Discussione informale a Miami, Florida, il 10 marzo 2025, alle 16:20 EST
- 27° Annual Global Healthcare Conference di Barclays - Incontri individuali a Miami, Florida, l'11 e 12 marzo 2025
Le presentazioni saranno trasmesse in diretta sul sito web delle relazioni con gli investitori di CAMP4, con registrazioni disponibili per 30 giorni dopo gli eventi.
CAMP4 Therapeutics (Nasdaq: CAMP), una empresa biotecnológica en etapa clínica enfocada en terapias de oligonucleótidos antisenso dirigidas al regRNA, ha anunciado su participación en tres importantes conferencias para inversores que se aproximan.
El presidente y CEO de la compañía, Josh Mandel-Brehm, presentará en:
- La 35ª Conferencia Anual de Ciencias de la Salud de Oppenheimer - Presentación corporativa virtual el 12 de febrero de 2025, a las 10:00 a.m. EST
- Conferencia Global de Salud de Leerink Partners - Charla informal en Miami, Florida, el 10 de marzo de 2025, a las 4:20 p.m. EST
- 27ª Conferencia Global Anual de Salud de Barclays - Reuniones uno a uno en Miami, Florida, del 11 al 12 de marzo de 2025
Las presentaciones se transmitirán en vivo en el sitio web de relaciones con los inversores de CAMP4, con repeticiones disponibles durante 30 días después de los eventos.
CAMP4 Therapeutics (Nasdaq: CAMP), regRNA를 타겟으로 하는 항센스 올리고뉴클레오타이드 치료에 집중하는 임상 단계의 생명공학 회사가 다가오는 주요 투자자 회의 세 곳에 참여할 것임을 발표했습니다.
회사의 대통령 겸 CEO인 Josh Mandel-Brehm이 발표할 행사:
- 오펜하이머 제35회 연례 의료 생명과학 회의 - 2025년 2월 12일 오전 10:00 EST에 가상 기업 발표
- 리어링크 파트너스 글로벌 헬스케어 회의 - 2025년 3월 10일 플로리다 마이애미에서 오후 4:20 EST에 진행되는 대담
- 바클레이스 제27회 연례 글로벌 헬스케어 회의 - 2025년 3월 11-12일 플로리다 마이애미에서의 일대일 미팅
발표는 CAMP4의 투자자 관계 웹사이트에서 실시간으로 웹캐스트되며, 이벤트 후 30일 동안 다시 시청할 수 있습니다.
CAMP4 Therapeutics (Nasdaq: CAMP), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies par oligonucleotides antisens ciblant le regRNA, a annoncé sa participation à trois grandes conférences pour investisseurs à venir.
Le président et PDG de l'entreprise, Josh Mandel-Brehm, fera une présentation lors de :
- La 35e Conférence Annuelle sur les Sciences de la Vie et de la Santé d'Oppenheimer - Présentation virtuelle de l'entreprise le 12 février 2025 à 10h00 EST
- Conférence Mondiale sur la Santé de Leerink Partners - Discussion informelle à Miami, Floride, le 10 mars 2025 à 16h20 EST
- 27e Conférence Annuelle Mondiale de la Santé de Barclays - Réunions individuelles à Miami, Floride, les 11 et 12 mars 2025
Les présentations seront diffusées en direct sur le site Web des relations avec les investisseurs de CAMP4, avec des rediffusions disponibles pendant 30 jours après les événements.
CAMP4 Therapeutics (Nasdaq: CAMP), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf regRNA-zielgerichtete Antisense-Oligonukleotid-Therapien konzentriert, hat seine Teilnahme an drei wichtigen bevorstehenden Investorenkonferenzen angekündigt.
Der Präsident und CEO des Unternehmens, Josh Mandel-Brehm, wird präsentieren auf:
- Oppenheimers 35. jährliche Gesundheits- und Lebenswissenschaftskonferenz - Virtuelle Unternehmenspräsentation am 12. Februar 2025 um 10:00 Uhr EST
- Leerink Partners Global Healthcare Conference - Gesprächsreihe in Miami, Florida, am 10. März 2025 um 16:20 Uhr EST
- Barclays 27. jährliche globale Gesundheitskonferenz - Einzelgespräche in Miami, Florida, am 11. und 12. März 2025
Die Präsentationen werden live auf der Investor Relations-Website von CAMP4 übertragen, mit Aufzeichnungen, die 30 Tage nach den Veranstaltungen verfügbar sind.
- None.
- None.
CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy protein levels, today announced that Josh Mandel-Brehm, President & CEO, will participate in the following upcoming investor conferences:
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | |||
| Format: | Corporate Presentation | ||
| Date and Time: | February 12, 2025, 10:00 a.m. EST | ||
| Location: | Virtual | ||
| Webcast Link: | Click Here | ||
| Leerink Partners Global Healthcare Conference | |||
| Format: | Fireside Chat | ||
| Date and Time: | March 10, 2025, 4:20 p.m. EST | ||
| Location: | Miami, Florida | ||
| Webcast Link: | Click Here | ||
| Barclays 27th Annual Global Healthcare Conference | |||
| Format: | One-on-one meetings | ||
| Date and Time: | March 11-12, 2025 | ||
| Location: | Miami, Florida | ||
The presentation will be webcast live and can be accessed on the investor relations page of CAMP4’s website at https://investors.camp4tx.com. A replay of the webcasts will be archived on the CAMP4 website for 30 days following the presentations.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of rare and prevalent genetic diseases where increasing healthy protein levels may offer meaningful therapeutic benefits. Our approach allows for targeted gene upregulation by harnessing a fundamental mechanism of how genes are controlled. To increase gene expression, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform™ enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X.
Contacts
Investor Relations:
Sandya von der Weid
LifeSci Advisors
svonderweid@lifesciadvisors.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
FAQ
When is CAMP4's presentation at the Oppenheimer Healthcare Conference 2025?
Which investor conferences will CAMP stock (CAMP) participate in during Q1 2025?
Where can I watch CAMP4's investor conference presentations?
What type of presentation will CAMP4 deliver at the Leerink Partners Conference 2025?
